News headlines about Athenex (NASDAQ:ATNX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Athenex earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.5617298698188 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Separately, Deutsche Bank AG assumed coverage on Athenex in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 target price for the company.
Shares of Athenex (ATNX) traded up 7.03% during midday trading on Friday, reaching $14.61. The company’s stock had a trading volume of 131,075 shares. The stock’s market capitalization is $594.42 million. The company has a 50 day moving average of $16.84 and a 200-day moving average of $16.41. Athenex has a 52 week low of $11.21 and a 52 week high of $20.79.
In other Athenex news, Director Song-Yi Zhang bought 328,637 shares of Athenex stock in a transaction dated Monday, June 19th. The stock was acquired at an average cost of $11.00 per share, with a total value of $3,615,007.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at $44,000. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Johnson Yiu Nam Lau bought 25,200 shares of Athenex stock in a transaction dated Monday, June 19th. The stock was acquired at an average cost of $11.00 per share, with a total value of $277,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,722,722 shares of the company’s stock, valued at approximately $29,949,942. The disclosure for this purchase can be found here.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Athenex (NASDAQ:ATNX) Stock Price” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/08/11/athenex-nasdaqatnx-receiving-somewhat-positive-news-coverage-analysis-shows-updated.html.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
What are top analysts saying about Athenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athenex Inc and related companies.